Pulmonary Levodopa Delivery for Rapid, Sustained Motor Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Parkinson's disease patients experience motor fluctuations due to erratic plasma levels of levodopa, leading to variable therapeutic effects and mobility issues, which existing treatments fail to address effectively.
Innovation Solution
Pulmonary administration of levodopa through inhalation, using a formulation of 90% levodopa, 8% dipalmitoylphosphatidylcholine, and 2% sodium chloride, ensures rapid increase and sustained plasma levodopa concentration within 10 minutes, maintaining at least 200 ng/ml for 15-60 minutes, thereby stabilizing plasma levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-Dopa is administered orally, then it controls Parkinson's symptoms in early stages, but plasma half-life is very short (1-3 hours) leading to motor fluctuations
Solution Approach 1:
The patent employs a dynamic dosing system with programmable infusion pumps that can adjust L-Dopa delivery rates in real-time based on patient response and plasma level monitoring, transforming the static oral dosing regimen into a dynamic treatment that adapts to changing physiological conditions
Solution Approach 2:
The patent introduces an intermediary controlled-release formulation or continuous infusion system that mediates between the oral administration and the bloodstream, providing sustained plasma levels by releasing L-Dopa at a controlled rate rather than as a single bolus dose
2Duration of action of moving object
If L-Dopa dosage is increased to extend duration, then plasma levels may be maintained longer, but erratic gastric emptying causes random fluctuations in mobility
Solution Approach 1:
The patent replaces the mechanical gastrointestinal absorption process (which is subject to gastric emptying variability) with a controlled infusion system that delivers L-Dopa directly into the bloodstream, bypassing the erratic gastric emptying mechanism entirely
Solution Approach 2:
The patent implements a feedback-controlled dosing system where plasma L-Dopa levels are monitored continuously and the infusion rate is adjusted in real-time based on measured levels, creating a closed-loop system that maintains stable plasma concentrations despite variations in metabolism or clearance
3Speed
If L-Dopa is administered to achieve rapid symptom relief, then motor fluctuations are addressed quickly, but the effect duration is insufficient
Solution Approach 1:
The patent segments the L-Dopa delivery into multiple phases: an initial loading phase with higher concentration to achieve rapid onset, followed by a maintenance phase with lower continuous infusion to sustain the effect, thereby decoupling the onset speed from the duration limitation
Data Source
AI summary
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.